Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for cerebral cavernous malformation
ChiCTR2100043189Phase 2Recruiting
- Sponsor
- Yichang First People's Hospital
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sirolimus in cerebral cavernous malformation (CCM) (2 arms), sponsored by Yichang First People's Hospital. Primary endpoint: Volume changes in cerebral cavernous malformation. Started Mar 2021; status: recruiting.
02
Drugs
sirolimus
03
Conditions
cerebral cavernous malformation (CCM)
Beyond the preview
Go deeper on ChiCTR2100043189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043189.